Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection

Journal of Viral Hepatitis

Volumn 20, Issue 6, 2013, Pages 404-413

  Osburn, W O ^a   Levine, J S ^a   Chattergoon, M A ^a   Thomas, D L ^a   Cox, A L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

acute infection; chemokine; cytokine; hepatitis c virus

Indexed keywords

CHEMOKINE; CYTOKINE; EOTAXIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS STRAIN;

ACUTE DISEASE; ADULT; CELL MOVEMENT; CHEMOKINE CCL11; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKIN-10; INTERLEUKIN-5; LONGITUDINAL STUDIES; MALE; MONOCYTE CHEMOATTRACTANT PROTEINS; PROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIREMIA;

EID: 84877582490     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12052     Document Type: Article

References (32)

1. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-348.
2. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC,. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42 (1): 104-112.
3. Ray SC, Thomas DL,. Hepatitis C. In:, Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Chuchill Livingstone, 2010: 2157-2185.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
5. Narumi S, Tominaga Y, Tamaru M, et al,. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 11: 5536-5544.
6. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM,. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24 (1): 6-9.
7. Yoneda S, Umemura T, Joshita S, et al,. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2011; 41 (6): 587-593.
8. Diago M, Castellano G, Garcia-Samaniego J, et al,. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55 (3): 374-379.
9. Cox AL, Netski DM, Mosbruger T, et al,. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 7: 951-958.
10. Osburn WO, Fisher BE, Dowd KA, et al,. Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. Gastroenterology 2010; 138 (1): 315-324.
11. Hsu M, Zhang J, Flint M, et al,. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 12: 7271-7276.
12. Logvinoff C, Major ME, Oldach D, et al,. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004; 27: 10149-10154.
13. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC,. Selection Pressure from Neutralizing Antibodies Drives Sequence Evolution during Acute Infection with Hepatitis C Virus. Gastroenterology 2009; 7: 2377-2386.
14. Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC,. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 2012; 55 (6): 1684-1691.
15. Hosomura N, Kono H, Tsuchiya M, et al,. HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci 2011; 56 (4): 1057-1064.
16. Almeida AR, Legrand N, Papiernik M, Freitas AA,. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regu-latory cells that controls CD4+ T cell numbers. J Immunol 2002; 9: 4850-4860.
17. Suzuki H, Kundig TM, Furlonger C, et al,. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 5216: 1472-1476.
18. Cabrera R, Tu ZK, Xu YL, et al,. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40 (5): 1062-1071.
19. Boettler T, Spangenberg HC, Neumann-Haefelin C, et al,. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79 (12): 7860-7867.
20. Manigold T, Bocker U, Chen J, et al,. Hepatitis B core antigen is a potent inductor of interleukin-18 in peripheral blood mononuclear cells of healthy controls and patients with hepatitis B infection. J Med Virol 2003; 71 (1): 31-40.
21. Bolacchi F, Sinistro A, Ciaprini C, et al,. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006; 144 (2): 188-196.
22. Ebinuma H, Nakamoto N, Li Y, et al,. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82 (10): 5043-5053.
23. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH,. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 10: 4772-4780.
24. Taylor A, Akdis M, Joss A, et al,. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 2007; 120 (1): 76-83.
25. Nelson DR, Tu Z, Soldevila-Pico C, et al,. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38 (4): 859-868.
26. Campbell HD, Tucker WQ, Hort Y, et al,. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci USA 1987; 84 (19): 6629-6633.
27. Mentink-Kane MM, Cheever AW, Thompson RW, et al,. IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 2004; 2: 586-590.
28. Broide D, Sriramarao P,. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001; 179: 163-172.
29. Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM,. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum 2009; 60 (7): 1932-1943.
30. Kalayci O, Sonna LA, Woodruff PG, Camargo CA Jr, Luster AD, Lilly CM,. Monocyte chemotactic protein-4 (MCP-4; CCL-13): a biomarker of asthma. J Asthma 2004; 41 (1): 27-33.
31. Tacke F, Trautwein C, Yagmur E, et al,. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol 2007; 22 (8): 1256-1264.
32. Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL,. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis 2011; 204 (11): 1730-1740.